Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Anelixis_Therapeutics
|
| gptkbp:CEO |
gptkb:Gregory_J._Flesher
|
| gptkbp:developedBy |
therapies for hearing loss
therapies for otitis media therapies for tinnitus |
| gptkbp:focusesOn |
otolaryngology
ear, nose, and throat disorders |
| gptkbp:foundedYear |
2009
|
| gptkbp:headquartersLocation |
Irvine, California, United States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Novus Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
pharmaceuticals |
| gptkbp:notableProduct |
OP0201
|
| gptkbp:publiclyTraded |
true
|
| gptkbp:renamed |
gptkb:Eledon_Pharmaceuticals
|
| gptkbp:status |
defunct
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:NVUS
|
| gptkbp:successor |
gptkb:Eledon_Pharmaceuticals
|
| gptkbp:website |
https://www.novustherapeutics.com/
|
| gptkbp:bfsParent |
gptkb:Sofinnova_Investments
|
| gptkbp:bfsLayer |
6
|